Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BioNano Genomics Inc (BNGO) vs FTAI Aviation Ltd (FTAI) Price & Performance

BioNano Genomics IncTrade
FTAI Aviation LtdTrade

Price performance (Past 24H)

Key statistics

BioNano Genomics Inc vs FTAI Aviation Ltd — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.66M), while FTAI Aviation Ltd trades at $226.26 (market cap $23.17B). The key difference: FTAI Aviation Ltd is far larger — about 1696.2× BioNano Genomics Inc's market cap, and FTAI Aviation Ltd pays a 0.89% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.

BNGOFTAI
Market Cap
$13.66M$23.17B
Sector
HealthIndustrials
52-Week High
$4.92$310.04
52-Week Low
$1.06$140.40
Enterprise Value
$16.26M$26.29B
Dividend Yield
0.89%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BioNano Genomics Inc

BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.

The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.

FTAI Aviation Ltd

FTAI Aviation trades at $226.66, up 5.42% today, with a neutral technical signal and mixed earnings history. Recent quarters have seen EPS misses against expectations, though revenue grew to $2.51B in 2025. The company maintains strong profitability margins and a 100% buy rating from analysts, with a consensus price target of $341.67. Key developments include a strategic collaboration for Boeing 737-800 freighters and a $1.465B gas turbine order, highlighting growth initiatives in aviation services and power segments.

The outlook for FTAI is positive based on analyst consensus and strategic growth in aviation and power markets, but risks include earnings volatility, high valuation multiples, and execution challenges in new segments. The stock offers potential upside to price targets, supported by institutional interest and dividend increases, yet investors should weigh near-term earnings performance against long-term growth prospects.

Returns comparison

Trailing returns across standard periods

About BioNano Genomics Inc

Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.

Read more on BNGO

About FTAI Aviation Ltd

FTAI Aviation owns and maintains a fleet of commercial aircraft and engines. It focuses on the specialized maintenance of the CFM56 engine, helping airlines reduce costs through efficient asset management.

Read more on FTAI